HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
17 mars 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
08 mars 2022 16h51 HE
|
HOOKIPA Pharma Inc.
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitorsPreclinical data suggest synergy of arenaviral...
HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
02 mars 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
01 mars 2022 16h01 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 01, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV
15 févr. 2022 16h06 HE
|
HOOKIPA Pharma Inc.
HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafterFinancial terms include $15...
HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
09 févr. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
18 janv. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
04 janv. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
03 déc. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
12 nov. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...